Deciphering the Increased Prevalence of TP53 Mutations in Metastatic Prostate Cancer

The prevalence of TP53 mutations in advanced prostate cancers (PCa) is 3 to 5 times of the quantity in primary PCa. By an integrative analysis of the Cancer Genome Atlas and Catalogue of Somatic Mutations in Cancer data, we revealed the supporting evidence for 2 complementary hypotheses: H(1) - TP53...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wensheng, Dong, Yan, Sartor, Oliver, Zhang, Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980432/
https://www.ncbi.nlm.nih.gov/pubmed/35392296
http://dx.doi.org/10.1177/11769351221087046

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980432/
https://www.ncbi.nlm.nih.gov/pubmed/35392296
http://dx.doi.org/10.1177/11769351221087046

Ejemplares similares